ImpediMed Limited
IPDQF
$0.01
$0.00-17.65%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.18M | 8.67M | 8.23M | 7.90M | 7.61M |
| Total Other Revenue | -- | -- | -- | -27.00K | -54.00K |
| Total Revenue | 9.18M | 8.67M | 8.23M | 7.90M | 7.61M |
| Cost of Revenue | 1.27M | 1.20M | 1.13M | 1.02M | 922.80K |
| Gross Profit | 7.91M | 7.48M | 7.10M | 6.88M | 6.69M |
| SG&A Expenses | 16.67M | 16.45M | 16.37M | 16.07M | 15.85M |
| Depreciation & Amortization | 2.88M | 2.90M | 2.95M | 2.56M | 2.18M |
| Other Operating Expenses | 2.59M | 2.55M | 2.53M | 2.84M | 3.16M |
| Total Operating Expenses | 23.55M | 23.24M | 23.12M | 22.66M | 22.30M |
| Operating Income | -14.36M | -14.57M | -14.89M | -14.76M | -14.69M |
| Income Before Tax | -15.69M | -15.30M | -15.01M | -14.46M | -13.98M |
| Income Tax Expenses | 18.70K | 17.70K | 16.80K | 16.30K | 15.90K |
| Earnings from Continuing Operations | -15.71 | -15.31 | -15.03 | -14.48 | -14.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.71M | -15.31M | -15.03M | -14.48M | -14.00M |
| EBIT | -14.36M | -14.57M | -14.89M | -14.76M | -14.69M |
| EBITDA | -12.69M | -12.87M | -13.14M | -13.00M | -13.03M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 8.10B | 8.09B | 8.08B | 8.08B | 8.09B |
| Average Diluted Shares Outstanding | 8.10B | 8.09B | 8.08B | 8.08B | 8.09B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |